RxDoctor Payments Data

Ahmad Karkoutly, MD

Internal Medicine · Brownsville, TXNPI 1780688382

Payments from drug & device makers

$434in general payments, 2019–2025

Across 14 payments — averaging $30.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$148
  • Novartis$84
  • Amarin Pharma, Inc.$42
  • GE HealthCare$37
  • Pfizer$31
  • Novo Nordisk$18
  • plus $73 from 5 others

What the payments were for

  • Food & beverage$41796%
  • Education$164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$434 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$426,859
Medicare patients
333
Services billed
4,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$127,839
JardianceEmpagliflozin86$108,598
EntrestoSacubitril/Valsartan80$101,630
OzempicSemaglutide92$87,148
XifaxanRifaximin27$61,290
JanuviaSitagliptin Phosphate42$48,671
FarxigaDapagliflozin Propanediol44$44,480
MounjaroTirzepatide26$25,659
XareltoRivaroxaban21$19,669
LinzessLinaclotide21$15,929
Clonidine75$13,001
RybelsusSemaglutide14$12,839
TradjentaLinagliptin23$12,667
ZenpepLipase/Protease/Amylase16$11,629
RexultiBrexpiprazole15$8,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$127,839177 claims
NovartisEntresto$84$101,63080 claims
Novo NordiskOzempic, Rybelsus$18$99,987106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Brownsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →